The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Official Title: Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Study ID: NCT03505944
Brief Summary: Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.
Detailed Description:
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Department of Hematology Aalborg University Hospital, Aalborg, , Denmark
Department of Hematology Aarhus University Hospital, Aarhus, , Denmark
Clinic of Hematology L-4241 Rigshospitalet, Copenhagen, , Denmark
Department of Hematology X Odense University Hospital, Odense, , Denmark
Hæmatologisk Afdeling Zeeland University Hospital, Roskilde, Roskilde, , Denmark
Department of Hematology Helsinki University Hospital Comprehensive Cancer Center, Helsinki, , Finland
Oulu University Hospital, Oulu, , Finland
Tampere University Hospital, Tampere, , Finland
Oslo University Hospital, Oslo, , Norway
Stavanger University Hospital, Stavanger, , Norway
St. Olav Hospital, Trondheim, , Norway
Department of Hematology Linköping University Hospital, Linköping, , Sweden
Department of Medicine Sunderbyn Hospital, Luleå, , Sweden
Skane University Hospital, Lund, , Sweden
Karolinska University Hospital, Stockholm, , Sweden
Department of Oncology Norrland University Hospital, Umeå, , Sweden
Uppsla Academic Hospital, Uppsala, , Sweden
Name: Mats Jerkeman
Affiliation: Skane University Hospital
Role: PRINCIPAL_INVESTIGATOR